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Our proposed experiments included: (a) immunizing mice with synthetic peptides, Co)
preparing spleen and lymph node ceils, (c) growing them under conventional conditions as well
as in the rotatory vessel in appropriate medium reconstituting with synthetic peptides and/or
cytokinesasneeded and (d) comparing at regular time intervals the specific CTL activity as well
as helper T-cell activity (in terms of both proliferative responses and cytokine production) using
established procedures in my laboratory. We further proposed that once we demonstrated the
merit of rotatory vessel technology to achieve desired results, these studies would be expanded
to include immune cells from non-human primates (rhesus monkeys and chimpanzees) and also
humans.
We conducted a number of experiments to determine CTL induction by the synthetic
peptides corresponding to antigenic proteins in HIV and HPV in different mouse strains that
express MHC haplotypes H-2b or H-2d. We immunized mice with 100 ug of the synthetic
peptide, suspended in sterile water, and emulsified in CFA (1:1). The immune lymph node
cells obtained after 7 days were re.stimulated by culturing in T25 flask, HARV-10, or STLV-50,
in the presence of the peptide at 20 ug/ml. The results from the 51Cr-release assay consistently
revealed complete abrogation of CTL activity of cells grown in the bioreactors (both HARV and
STLV), while significant antigen-specific CTL activity was observed with cells cultured in
tissue culture flasks.
This data showing abrogation of _ activity of cells cultured in the bioreactors under
the in vivo mimicking 3D-conditions was rather surprising to us. However, there were few
reports in the literature regarding diminished cellular immune responses observed in people after
either short- or long-term space travel. But, none of these reports dealt with studies related to
either antigen-specificity or CTL activity. Therefore, our results, though disappointing with
respect to our intention of using the bioreactor technology for enhancing immune function, are
new and informative. We therefore proposed new studies for the TMC-NASA contract round II
application, to understand the mechanism of this observed loss of immune function for cells
cultured in microgravity. Thus far, it appears that this loss in immune function under
microgravity relates to loss of a particular type of immune cell population called antigen-
presenting cells. We are conducting detailed studies to further understand this phenomenon.
Thus, overall the data we generated in this study proved the usefulness of the NASA-
developed bioreactor technology for understanding the known immune deficiency during space
travel. Additionally, this ex vivo microgravity technology since it mimics effectively the in vivo
situation, it is also useful in understanding immune disorders in general. Thus, our proposed
studies in TMC-NASA contract round 1I application benefit from data generated in this TMC-
NASA contract round I study.
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